AbbVie Sees 37% Drop In Humira Sales This Year As Biosimilars Hit U.S. Market
AbbVie Inc said on Thursday it expects sales of its flagship rheumatoid arthritis drug Humira to decline 37% this year due to competition from cheaper biosimilars in the United States, but sees that